Clinical trial
Study of CEP-701 (Lestaurtinib) in Patients With Acute Myeloid Leukemia (AML)
NCT00079482 · Cephalon, Industry · Completed
Key facts
| NCT number | NCT00079482 |
|---|---|
| Title | Study of CEP-701 (Lestaurtinib) in Patients With Acute Myeloid Leukemia (AML) |
| Official title | A Randomized, Open-Label Study of Oral CEP-701 Administered in Sequence With Standard Chemotherapy to Patients With Relapsed Acute Myeloid Leukemia (AML) Expressing FLT-3 Activating Mutations |
| Lead sponsor | Cephalon, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Acute Myeloid Leukemia |
| Intervention type | Drug |
| Interventions | CEP-701, high-dose cytarabine, Mitozantrone, Etoposide, Cytarabine (combination Chemotherapy) |
| Enrollment | 224 |
| Start date | Oct 1, 2003 |
| Primary completion | Mar 1, 2009 |
| Completion | Jan 1, 2010 |
| First posted | Mar 10, 2004 |
| Last update posted | Jul 21, 2016 |
| Countries | Australia, Canada, Germany, Israel, Italy, New Zealand, Poland, Romania, Russia, Spain, Sweden, Ukraine and 1 more |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: